Furthermore, the risk of polyendocrinopathy appears to be elevated when LAG-3 inhibitors are used in combination with PD-1 blockade, with reported occurrences of adrenalitis, hypophysitis, and thyroiditis [25,29]. This evidence concerns the gene LAG3 and polyendocrinopathy.